Pharmacological treatment
Crohn’s Disease, Ulcerative Colitis
ADVERSE EFFECTS, RECURRENCE, ULCERATIVE COLITIS
Patients in the endoscopic treatment arm will be maintained on the same pharmacological treatment that they were receiving at the time of the procedure whenever possible, adjusted for the occurrence of adverse effects (AEs) or loss of efficacy (e.g. occurrence of antibodies and undetectable drug levels). Patients in the surgery branch will receive treatment to prevent post-surgical recurrence in line with the recommendations of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU) [